Cingulate (CING) Short-term Investments (2021 - 2022)

Cingulate's (CING) quarterly Short-term Investments came in at $7.5 million in Q2 2022, up 805430.12% on a QoQ basis from $933.0 in Q1 2022.

Cingulate (CING) Short-term Investments (2021 - 2022) Analysis & Trends

Cingulate (CING) has 2 years of Short-term Investments data on file, last reported at $7.5 million in Q2 2022.

Quarterly Short-term Investments changed N/A year-over-year to $7.5 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.5 million (changed N/A YoY) and the FY2021 annual result came in at $933.0, changed N/A from the prior year.
Short-term Investments climbed to $7.5 million in Q2 2022, from $933.0 in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $7.5 million in Q2 2022 to a low of $933.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cingulate	72.85 Mn	72.85 Mn	-

Download Data